Logo
A worldwide community exchanges ideas, shares learnings, and accelerates CGT breakthroughs.

Empower cells. Empower lives. Together.

Connecting experts. Driving innovation.

For over 30 years, Miltenyi Biotec has helped shape cell and gene therapy (CGT) with integrated technologies, workflows, and services. From discovery to clinical translation and commercial manufacturing, we partner with clinicians and innovators around the world and deliver:

  • Proven expertise in immunotherapy, gene-modified cells, and graft engineering.
  • Scalable, automated workflows for consistent, high-quality results.
  • A strong focus on point-of-care models to bring therapies closer to patients.

Join our global network

Breakthroughs happen when experts share insights. That’s why we’ve built an open, practice-driven network of clinicians, researchers, and manufacturing specialists worldwide. Together, we accelerate learning, align on regulatory best practices, and remove barriers to patient access.

What you get

A tailored newsletter

Take a peek at our monthly newsletter with stories, assets, and events delivered directly to your mailbox.

Check it out

Events that drive change

Engage with colleagues at our flagship event MACS® CGT Days, local networking events, conferences, and more.

Get involved

Expert talks

Access webinars, conference talks, and panel discussions for the latest developments and opinions in the field.

Browse media

Dedicated training courses

Prepare with Miltenyi University! Discover hands-on and online training courses for clinical cell manufacturing.

Grow your skills

Together, setting the benchmark in CGT solutions

Pioneering more than 200 cell therapy trials with PoC manufacturing and analytics*

Approved engineered T cell therapies are manufactured using Miltenyi Biotec's solutions**

Over 25 years of CGT expertise and relentlessly pushing boundaries

*Active cell therapy trials and hospital treatments using CliniMACS® Instruments for manufacturing and/or analytics of cell products
** Approved cell therapies and gene-modified cell therapies in EU and USA, excluding minimally manipulated cell therapies, cord blood products, and tissue-engineered therapies

Come be part of the change